Posted by Michael Wonder on 20 Nov 2021
EMA starts review of Paxlovid for treating patients with COVID-19
19 November 2021 - EMA is reviewing currently available data on the use of Paxlovid (PF-07321332/ritonavir), an oral treatment for COVID-19 developed by Pfizer.
EMA is starting this review to support national authorities who may decide on its early use for COVID-19, for example in emergency use settings, prior to marketing authorisation.
